<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03010332</url>
  </required_header>
  <id_info>
    <org_study_id>ATA230-EAP-201</org_study_id>
    <nct_id>NCT03010332</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease</brief_title>
  <official_title>An Expanded Access Protocol of ATA230 (Third-Party Donor-Derived Cytomegalovirus-Specific T Cells) for the Treatment of CMV Viremia or Disease in Subjects for Whom There Are No Other Comparable Options</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Atara Biotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Atara Biotherapeutics</source>
  <brief_summary>
    <textblock>
      This is an expanded access protocol designed to provide access of ATA230 to subjects with&#xD;
      cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard&#xD;
      antiviral therapy and have no comparable treatment options.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically&#xD;
      kill cells presenting CMV protein antigens.&#xD;
&#xD;
      This is an expanded access protocol designed to provide access of ATA230 to subjects with CMV&#xD;
      viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no&#xD;
      comparable treatment options. This study will enroll subjects regardless of the underlying&#xD;
      susceptibility to CMV, including allogeneic hematopoietic cell transplant (alloHCT), solid&#xD;
      organ transplant (SOT), human immunodeficiency virus (HIV), other immunocompromised states,&#xD;
      and immune competent subjects who require therapy. Subjects must have active CMV viremia or&#xD;
      disease for ≥ 2 weeks despite treatment with antiviral therapy or must be intolerant to&#xD;
      antiviral therapy due to treatment-related toxicity or comorbidities such as renal&#xD;
      insufficiency or myelosuppression.&#xD;
&#xD;
      ATA230 will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects&#xD;
      will receive intravenous (IV) ATA230 at a dose of 1×10^6 cells/kg (with an acceptable range&#xD;
      of 0.8-1.0×10^6 cells/kg) on Days 1, 8, and 15, followed by observation through Day 35.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <condition>CMV Viremia</condition>
  <condition>CMV Disease</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)</intervention_name>
    <description>ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.</description>
    <other_name>ATA230</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A subject will be considered eligible to participate in the study if the following&#xD;
        inclusion criteria are satisfied:&#xD;
&#xD;
          1. Has a clinically documented condition associated with CMV disease (eg, interstitial&#xD;
             pneumonia, hepatitis, encephalitis, retinitis, colitis) or microbiological evidence of&#xD;
             CMV viremia or tissue invasion with CMV infection (as determined by viral culture or&#xD;
             levels of CMV DNA in blood or body fluids)&#xD;
&#xD;
          2. The CMV disease or CMV viremia is characterized by at least one of the following:&#xD;
&#xD;
               1. CMV disease is persistent or clinically progressing despite ≥ 2 weeks of&#xD;
                  antiviral therapy&#xD;
&#xD;
               2. CMV viremia/disease is persistent or increasing (determined by quantitation of&#xD;
                  blood CMV DNA) despite ≥ 2 weeks of antiviral therapy&#xD;
&#xD;
               3. A genetic mutation associated with antiviral drug resistance is present&#xD;
&#xD;
               4. Unable to continue antiviral drugs due to drug-associated toxicity.&#xD;
&#xD;
          3. No other comparable or satisfactory therapies are available for treatment of CMV&#xD;
&#xD;
          4. Not eligible for any other trials supporting development of ATA230&#xD;
&#xD;
          5. For subjects who received an alloHCT, the underlying disease for which the alloHCT was&#xD;
             performed is in morphologic remission&#xD;
&#xD;
          6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt; 3× the upper&#xD;
             limit of normal (ULN) and total bilirubin &lt; 2.5×ULN unless caused by CMV&#xD;
&#xD;
          7. Availability of appropriate ATA230 cell lot (ie, HLA partially-matched and restricted&#xD;
             CMV-CTLs)&#xD;
&#xD;
          8. Subject or subject's representative is willing and able to provide written informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A subject will not be eligible to participate in the study if any of the following criteria&#xD;
        are met:&#xD;
&#xD;
          1. Receiving concomitant investigational therapy (co-enrollment in a non-interventional&#xD;
             study or a study for follow-up or sample collection only is permitted)&#xD;
&#xD;
          2. Need for antimetabolite agents (eg, methotrexate), or extracorporeal photopheresis&#xD;
&#xD;
          3. Antithymocyte globulin or similar anti-T cell antibody therapy ≤ 4 weeks prior to the&#xD;
             first dose of ATA230 (on Day 1 of Cycle 1)&#xD;
&#xD;
          4. Need for vasopressor or ventilator support&#xD;
&#xD;
          5. Pregnancy, except when ATA230 is clearly needed&#xD;
&#xD;
          6. Female of childbearing potential or male with a female partner of childbearing&#xD;
             potential unwilling to use a highly effective method of contraception&#xD;
&#xD;
          7. Inability to comply with study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Willis Navarro, MD</last_name>
    <role>Study Director</role>
    <affiliation>Atara Biotherapeutics</affiliation>
  </overall_official>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>April 4, 2019</last_update_submitted>
  <last_update_submitted_qc>April 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cytomegalovirus</keyword>
  <keyword>Cytomegalovirus Viremia</keyword>
  <keyword>Cytomegalovirus Infection</keyword>
  <keyword>CMV Infection</keyword>
  <keyword>Hematopoietic Cell Transplant</keyword>
  <keyword>Solid Organ Transplant</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>Cytomegalovirus Disease</keyword>
  <keyword>Hematopoietic Stem Cell Transplant</keyword>
  <keyword>CMV</keyword>
  <keyword>CMV syndrome</keyword>
  <keyword>Cytomegalovirus syndrome</keyword>
  <keyword>CMV disease</keyword>
  <keyword>CMV viremia</keyword>
  <keyword>allogeneic</keyword>
  <keyword>third-party</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03010332
org study id: ATA230-EAP-201
nct id: NCT03010332
lead sponsor: 
This is an expanded access protocol designed to provide access of ATA230 to subjects with
      cytomegalovirus (CMV) viremia or disease, who are intolerant to, or failed, standard
      antiviral therapy and have no comparable treatment options.
ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically
      kill cells presenting CMV protein antigens.

      This is an expanded access protocol designed to provide access of ATA230 to subjects with CMV
      viremia or disease, who are intolerant to, or failed, standard antiviral therapy and have no
      comparable treatment options. This study will enroll subjects regardless of the underlying
      susceptibility to CMV, including allogeneic hematopoietic cell transplant (alloHCT), solid
      organ transplant (SOT), human immunodeficiency virus (HIV), other immunocompromised states,
      and immune competent subjects who require therapy. Subjects must have active CMV viremia or
      disease for ≥ 2 weeks despite treatment with antiviral therapy or must be intolerant to
      antiviral therapy due to treatment-related toxicity or comorbidities such as renal
      insufficiency or myelosuppression.

      ATA230 will be administered in cycles lasting 5 weeks (35 days). During each cycle, subjects
      will receive intravenous (IV) ATA230 at a dose of 1×10^6 cells/kg (with an acceptable range
      of 0.8-1.0×10^6 cells/kg) on Days 1, 8, and 15, followed by observation through Day 35.
intervention type: Biological
intervention name: Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)
description: ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
other name: ATA230
criteria: 
gender: All
minimum age: N/A
maximum age: N/A
last name: Willis Navarro, MD
role: Study Director
affiliation: Atara Biotherapeutics
responsible party type: Sponsor
mesh term: Viremia